WELDING GmbH & Co. KG announces an important regulatory milestone in Europe. Following the successful closure of the Decentralized Procedure (DCP) earlier this year, WELDING GmbH & Co. KG in collaboration with its partner Zenara Pharma Pvt Ltd has received its first marketing authorizations in Europe for Tafamidis 61 mg soft capsules. WELDING is among the first company in Europe to obtain multi country generic approval for this product, underlining the company’s regulatory expertise and its focus on enabling timely market access through structured and reliable development and registration pathways.
This development further expands the company’s Finished Dosage Form (FDF) portfolio and reflects its focus on reliable, responsible, and sustainable partnership models across the pharmaceutical value chain. WELDING PHARMA FDF supports partners with value-oriented solutions ranging from development and market access support to long term supply concepts.
“With this milestone, we continue to strengthen our role as a reliable partner for the pharmaceutical industry,” said Lars Hallmayer, Managing Director, WELDING GmbH & Co. KG. “Our approach combines regulatory expertise, transparent collaboration, and a long-term commitment to responsible business practices.”
The company views this authorization as part of its broader strategy to create sustainable economic value through trusted partnerships and international market expertise. With decades of experience in the pharmaceutical sector and a strong global network, WELDING PHARMA FDF works closely with partners to develop and implement tailored product and licensing solutions.
Further steps toward market availability will be taken in accordance with applicable national requirements.
For media inquiries, please contact:
https://welding.eu/...
This development further expands the company’s Finished Dosage Form (FDF) portfolio and reflects its focus on reliable, responsible, and sustainable partnership models across the pharmaceutical value chain. WELDING PHARMA FDF supports partners with value-oriented solutions ranging from development and market access support to long term supply concepts.
“With this milestone, we continue to strengthen our role as a reliable partner for the pharmaceutical industry,” said Lars Hallmayer, Managing Director, WELDING GmbH & Co. KG. “Our approach combines regulatory expertise, transparent collaboration, and a long-term commitment to responsible business practices.”
The company views this authorization as part of its broader strategy to create sustainable economic value through trusted partnerships and international market expertise. With decades of experience in the pharmaceutical sector and a strong global network, WELDING PHARMA FDF works closely with partners to develop and implement tailored product and licensing solutions.
Further steps toward market availability will be taken in accordance with applicable national requirements.
For media inquiries, please contact:
https://welding.eu/...
